<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Quetiapine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01224</strong>&#160; (APRD00675)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Quetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01224/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01224/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01224.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01224.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01224.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01224.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01224.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01224">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Quetiapine fumarate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Quetiapine hemifumarate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Seroquel</td><td>AstraZeneca</td></tr><tr><td>Seroquel XR</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>111974-69-7</td></tr><tr><th>Weight</th><td>Average: 383.507<br>Monoisotopic: 383.166747749</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>25</sub>N<sub>3</sub>O<sub>2</sub>S</td></tr><tr><th>InChI Key</th><td>URKOMYMAXPYINW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H25N3O2S/c25-14-16-26-15-13-23-9-11-24(12-10-23)21-17-5-1-3-7-19(17)27-20-8-4-2-6-18(20)22-21/h1-8,25H,9-16H2</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-[2-(4-{2-thia-9-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,9,12,14-heptaen-10-yl}piperazin-1-yl)ethoxy]ethan-1-ol</div></td></tr><tr><th>SMILES</th><td><div class="wrap">OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiazepines</td></tr><tr><th>Subclass</th><td>Dibenzothiazepines</td></tr><tr><th>Direct parent</th><td>Dibenzothiazepines</td></tr><tr><th>Alternative parents</th><td>Benzene and Substituted Derivatives; Diazinanes; Piperazines; Tertiary Amines; Ethers; Primary Alcohols; Polyamines; Carboxamidines; Thioethers</td></tr><tr><th>Substituents</th><td>1,4-diazinane; benzene; piperazine; tertiary amine; thioether; amidine; carboxylic acid amidine; primary alcohol; ether; polyamine; organonitrogen compound; amine; alcohol</td></tr><tr><th>Classification description</th><td>This compound belongs to the dibenzothiazepines. These are compounds containing a dibenzothiazepine moiety, which consists of two benzene connected by a thiazepine ring.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of schizophrenia and related psychotic disorders.</td></tr><tr><th>Pharmacodynamics</th><td>Quetiapine is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Quetiapine is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT<sub>2</sub>), and dopamine type 2 (D2) receptors. Quetiapine is an antagonist at serotonin 5-HT<sub>1A</sub> and 5HT<sub>2</sub>, dopamine D1 and D2, histamine H1, and adrenergic alpha 1 and alpha 2 receptors. Quetiapine has no significant affinity for cholinergic muscarinic or benzodiazepine receptors. Drowsiness and orthostatic hypotension associated with use of quetiapine may be explained by its antagonism of histamine H1 and adrenergic alpha 1 receptors, respectively. Quetiapine's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug.</td></tr><tr><th>Mechanism of action</th><td>Quetiapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.</td></tr><tr><th>Absorption</th><td>Rapidly and well absorbed.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>10&#177;4 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>83%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic. The major metabolic pathways are sulfoxidation, mediated by cytochrome P450 3A4 (CYP3A4), and oxidation of the terminal alcohol to a carboxylic acid. The major sulfoxide metabolite of quetiapine is inactive. Quetiapine also undergoes hydroxylation of the dibenzothiazepine ring, O-deakylation, N-dealkylation, and phase II conjugation. The 7-hydroxy and 7-hydroxy-
N-delakylated metabolites appear to be active, but are present in very low concentrations.</p></td></tr><tr><th>Route of elimination</th><td>Elimination of quetiapine is mainly via hepatic metabolism. Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized. Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.</td></tr><tr><th>Half life</th><td>6 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include drowsiness and sedation, tachycardia, and hypotension.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9155</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9906</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6037</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8424</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.9117</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.9325</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5554</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6438</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Substrate</td>
        <td>0.8919</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-substrate</td>
        <td>0.6049</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.5744</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.6305</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Inhibitor</td>
        <td>0.588</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7033</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.7961</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.5375</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7479
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.869
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.6537 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9483
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.8684
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Astrazeneca pharmaceuticals lp</li>
<li>Astrazeneca lp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Advanced Pharmaceutical Services Inc.</li>
<li><a href="http://www.aqpharmaceuticals.com">AQ Pharmaceuticals Inc.</a></li>
<li><a href="http://orders.a-smeds.com">A-S Medication Solutions LLC</a></li>
<li><a href="http://www.astrazeneca.ca">AstraZeneca Inc.</a></li>
<li><a href="http://www.atlanticbiologicals.com">Atlantic Biologicals Corporation</a></li>
<li><a href="http://bryantranchprepack.com">Bryant Ranch Prepack</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Coupler Enterprises Inc.</li>
<li>Direct Dispensing Inc.</li>
<li>Heartland Repack Services LLC</li>
<li><a href="http://www.innoviantpharmacy.com">Innoviant Pharmacy Inc.</a></li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li>Neuman Distributors Inc.</li>
<li><a href="http://www.norwichpharma.com">Norwich Pharmaceuticals Inc.</a></li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pdrx.com">PD-Rx Pharmaceuticals Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.prepaksys.com">Prepak Systems Inc.</a></li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.southwoodhealthcare.com">Southwood Pharmaceuticals</a></li>
<li>Tya Pharmaceuticals</li>
<li>Vangard Labs Inc.</li>
<li><a href="http://www.wyeth.com">Wyeth Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>100 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>200 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>25 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>300 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>400 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>50 mg</td></tr><tr><td>Tablet, film coated, extended release</td><td>Oral</td><td>150 mg</td></tr><tr><td>Tablet, film coated, extended release</td><td>Oral</td><td>200 mg</td></tr><tr><td>Tablet, film coated, extended release</td><td>Oral</td><td>300 mg</td></tr><tr><td>Tablet, film coated, extended release</td><td>Oral</td><td>400 mg</td></tr><tr><td>Tablet, film coated, extended release</td><td>Oral</td><td>50 mg</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Seroquel 400 mg tablet</td><td>16.71USD</td><td>tablet</td></tr><tr><td>Seroquel xr 400 mg tablet</td><td>14.82USD</td><td>tablet</td></tr><tr><td>Seroquel 300 mg tablet</td><td>14.21USD</td><td>tablet</td></tr><tr><td>Seroquel xr 300 mg tablet</td><td>12.61USD</td><td>tablet</td></tr><tr><td>Seroquel 200 mg tablet</td><td>10.84USD</td><td>tablet</td></tr><tr><td>SEROquel XR 200 mg 24 Hour tablet</td><td>10.0USD</td><td>tablet</td></tr><tr><td>Seroquel xr 200 mg tablet</td><td>9.62USD</td><td>tablet</td></tr><tr><td>SEROquel XR 150 mg 24 Hour tablet</td><td>9.09USD</td><td>tablet</td></tr><tr><td>Seroquel xr 150 mg tablet</td><td>8.74USD</td><td>tablet</td></tr><tr><td>Seroquel 100 mg tablet</td><td>5.75USD</td><td>tablet</td></tr><tr><td>Seroquel 50 mg tablet</td><td>5.5USD</td><td>tablet</td></tr><tr><td>SEROquel XR 50 mg 24 Hour tablet</td><td>5.06USD</td><td>tablet</td></tr><tr><td>Seroquel xr 50 mg tablet</td><td>4.87USD</td><td>tablet</td></tr><tr><td>Seroquel 300 mg Tablet</td><td>4.35USD</td><td>tablet</td></tr><tr><td>Seroquel 25 mg tablet</td><td>3.35USD</td><td>tablet</td></tr><tr><td>Seroquel 200 mg Tablet</td><td>2.98USD</td><td>tablet</td></tr><tr><td>Apo-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Co Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Jamp-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Mylan-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Novo-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Pms-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Ratio-Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Sandoz Quetiapine 300 mg Tablet</td><td>2.44USD</td><td>tablet</td></tr><tr><td>Apo-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Co Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Jamp-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Mylan-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Novo-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Pms-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Ratio-Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Sandoz Quetiapine 200 mg Tablet</td><td>1.67USD</td><td>tablet</td></tr><tr><td>Seroquel 100 mg Tablet</td><td>1.48USD</td><td>tablet</td></tr><tr><td>Novo-Quetiapine 150 mg Tablet</td><td>1.42USD</td><td>tablet</td></tr><tr><td>Apo-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Co Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Jamp-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Mylan-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Novo-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Pms-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Ratio-Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Sandoz Quetiapine 100 mg Tablet</td><td>0.83USD</td><td>tablet</td></tr><tr><td>Seroquel 25 mg Tablet</td><td>0.56USD</td><td>tablet</td></tr><tr><td>Apo-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Co Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Jamp-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Mylan-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Novo-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Pms-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Ratio-Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr><tr><td>Sandoz Quetiapine 25 mg Tablet</td><td>0.31USD</td><td>tablet</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>5948437</td><td>1997-11-28</td><td>2017-11-28</td></tr><tr><td>United States</td><td>4879288</td><td>1994-09-26</td><td>2011-09-26</td></tr><tr><td>Canada</td><td>2251944</td><td>2007-04-10</td><td>2017-05-27</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>solid</td></tr><tr><th>Experimental Properties</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr><tr><td>water solubility</td><td>Moderate</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>logP</td><td>2.8</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></table></td></tr><tr><th>Predicted Properties</th><td class="data-table-container"><table class="table table-condensed table-striped"><thead><tr><th class="head-medium">Property</th><th class="head-large">Value</th><th>Source</th></tr></thead><tbody><tr><td>water solubility</td><td>4.03e-02 g/l</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.93</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>logP</td><td>2.81</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#logp_logd">ChemAxon</a></td></tr><tr><td>logS</td><td>-4</td><td><a href="http://www.vcclab.org/lab/alogps/" target="_blank">ALOGPS</a></td></tr><tr><td>pKa (strongest acidic)</td><td>15.12</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>pKa (strongest basic)</td><td>7.06</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>physiological charge</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka">ChemAxon</a></td></tr><tr><td>hydrogen acceptor count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>hydrogen donor count</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#h_bond">ChemAxon</a></td></tr><tr><td>polar surface area</td><td>48.3</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topolgical_surface">ChemAxon</a></td></tr><tr><td>rotatable bond count</td><td>5</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>refractivity</td><td>114.09</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#refractivity">ChemAxon</a></td></tr><tr><td>polarizability</td><td>42.78</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>number of rings</td><td>4</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/property-calculations/#topology_analysis">ChemAxon</a></td></tr><tr><td>bioavailability</td><td>1</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>rule of five</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Ghose filter</td><td>Yes</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>Veber's rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr><tr><td>MDDR-like rule</td><td>No</td><td><a href="http://www.chemaxon.com/products/calculator-plugins/molecular-modelling/#polarization">ChemAxon</a></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="citations"><p><a href="http://www.drugsyn.org/Quetiapine.htm">DrugSyn.org</a></p></span><a class="wishart-link-out" href="https://www.google.com/?tbm=pts#q=4879288&amp;tbm=pts" target="_blank">US4879288 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Dev V, Raniwalla J: Quetiapine: a review of its safety in the management of schizophrenia. Drug Saf. 2000 Oct;23(4):295-307. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11051217">Pubmed</a></li>
	<li>Mukaddes NM, Abali O: Quetiapine treatment of children and adolescents with Tourette&#8217;s disorder. J Child Adolesc Psychopharmacol. 2003 Fall;13(3):295-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14642017">Pubmed</a></li>
	<li>Tallerico T, Novak G, Liu IS, Ulpian C, Seeman P: Schizophrenia: elevated mRNA for dopamine <acronym title="Longer"><span class="caps">D2</span></acronym> receptors in frontal cortex. Brain Res Mol Brain Res. 2001 Mar 5;87(2):160-5. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11245917">Pubmed</a></li>
	<li>Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18537577">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>KEGG Compound</td><td><a class="wishart-link-out" href="http://www.genome.jp/dbget-bin/www_bget?cpd:C07397" target="_blank">C07397 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Compound</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5002" target="_blank">5002 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PubChem Substance</td><td><a class="wishart-link-out" href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46504800" target="_blank">46504800 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChemSpider</td><td><a class="wishart-link-out" href="http://www.chemspider.com/Chemical-Structure.4827.html" target="_blank">4827 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEBI</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chebi/searchId.do?chebiId=8707" target="_blank">8707 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>ChEMBL</td><td><a class="wishart-link-out" href="http://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL716" target="_blank">CHEMBL716 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Therapeutic Targets Database</td><td><a class="wishart-link-out" href="http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000001" target="_blank">DAP000001 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA451201" target="_blank">PA451201 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>IUPHAR</td><td><a class="wishart-link-out" href="http://www.iuphar-db.org/DATABASE/LigandDisplayForward?ligandId=50" target="_blank">50 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Guide to Pharmacology</td><td><a class="wishart-link-out" href="http://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=50" target="_blank">50 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drug Product Database</td><td><a class="wishart-link-out" href="http://205.193.93.51/dpdonline/searchRequest.do?din=2240862" target="_blank">2240862 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/cgi/generic2/quetiap.htm" target="_blank">http://www.rxlist.com/cgi/generic2/quetiap.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/cdi/quetiapine.html" target="_blank">http://www.drugs.com/cdi/quetiapine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ser1402.shtml" target="_blank">http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/ser1402.shtml <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Quetiapine" target="_blank">Quetiapine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>N05AH04<ul class="atc-drug-tree"><li><a href="/atc/N#N">N &#8212; NERVOUS SYSTEM</a></li><li><a href="/atc/N05#N05">N05 &#8212; PSYCHOLEPTICS</a></li><li><a href="/atc/N05A#N05A">N05A &#8212; ANTIPSYCHOTICS</a></li><li><a href="/atc/N05AH#N05AH">N05AH &#8212; Diazepines, oxazepines, thiazepines and oxepines</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>28:16.08.04</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01224.pdf?1265922799">show</a>(273 KB)</td></tr><tr><th>MSDS</th><td><a href="/system/msds/DB01224.pdf?1265922739">show</a>(57.1 KB)</td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>The macrolide, clarithromycin, may increase the effect and toxicity of quetiapine.</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>The macrolide, erythromycin, may increase the effect and toxicity of quetiapine.</td></tr><tr><td><a href="/drugs/DB00754">Ethotoin</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB06414">Etravirine</a></td><td>Quetiapine, when used concomitantly with etravirine (a strong CYP3A4 inducer), may experience a decrease in serum concentration. It is recommended to increase quetiapine dosage if concurrent therapy is required.</td></tr><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the therapeutic and adverse effects of quetiapine.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00532">Mephenytoin</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>Phenytoin decreases the effect of quetiapine</td></tr><tr><td><a href="/drugs/DB01369">Quinupristin</a></td><td>This combination presents an increased risk of toxicity</td></tr><tr><td><a href="/drugs/DB00989">Rivastigmine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>The therapeutic effects of the central acetylcholinesterase inhibitor (AChEI), Tacrine, and/or the anticholinergic/antipsychotic, Quetiapine, may be reduced due to antagonism. This interaction may be beneficial when the anticholinergic action is a side effect. AChEIs may also augment the central neurotoxic effect of antipsychotics. Monitor for extrapyramidal symptoms and decreased efficacy of both agents.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolongation may occur increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Quetiapine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Quetiapine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>May cause dopamine deficiency. Monitor for Tetrabenazine adverse effects.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. </td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration.</td></tr><tr><td><a href="/drugs/DB00662">Trimethobenzamide</a></td><td>Trimethobenzamide and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>Triprolidine and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhance their adverse/toxic effects. Additive CNS depressant effects may also occur. Monitor for enhanced anticholinergic and CNS depressant effects.</td></tr><tr><td><a href="/drugs/DB00209">Trospium</a></td><td>Trospium and Quetiapine, two anticholinergics, may cause additive anticholinergic effects and enhanced adverse/toxic effects. Monitor for enhanced anticholinergic effects.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of quetiapine by decreasing its metabolism. Additive QTc prolongation may also occur. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of quetiapine if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP).</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take without regard to meals.</li></ul></td></tr></tbody></table>